Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
IPO Year:
Exchange: NASDAQ
Website: artelobio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2025 | $20.00 | Hold → Buy | D. Boral Capital |
| 11/1/2021 | $4.00 | Buy | HC Wainwright & Co. |
Fastest customizable press release news feed in the world
SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants to purchase up to 6,376,814 shares of common stock, at a combined purchase price of $3.45 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds from the offering were approximately $11.0 million, prior to deducting placement agent fees and other offering expenses payable by the Company. The Com
SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants to purchase up to 6,376,814 shares of common stock, at a combined purchase price of $3.45 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.20 per share, will be exercisable upon issuance and will expire five and one-half years from the Effectivenes
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced a strategic expansion opportunity for ART27.13 in muscle preservation for patients undergoing glucagon-like peptide-1 ("GLP-1") receptor agonist therapy. The initiative is supported by four significant developm
BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinical study—an announcement that underscores a broader story: a multi-platform biotech pipeline built for durability across several high-value therapeutic areas. Artelo Biosciences is running three distinct clinical-stage programs — in oncology support, neuropathic pain, and CNS disorders — while simultaneously expanding its lead compound into ophthalmology through fully externally funded studies. This isn't a one-trick biotech. It's a platform play in one of
DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Today's action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the biologics market surging toward $650 billion+ by 2030 and medical tourism accelerating, today's developments showcase capital-efficient clinical progress, high-growth partnerships, and operational scaling, creating compelling narratives in precision medicine, oncology adjuvants, and AI-enabled workforce solutions. Artelo Biosciences (NASDAQ:ARTL) expands ART27.13's clinical footprint into ophthalmology through a fully funded investigator-initiated study agree
BRISTOL, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences (NASDAQ:ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial (IST) is backed by Glaucoma UK and the HSC R&D Division, with first patient enrollment anticipated in Q2 2026. The announcement represents a significant pipeline diversification for the San Diego-based clinical-stage biopharmaceutical company — and one that does not require dilutive equity financing from shareholders. A $16.3 Billion Market Growing Faster Than Its Treatment Options The global glaucoma market was valued at USD 9.46 billion in 202
Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13's clinical potential into ophthalmology First patient enrollment anticipated in Q2 2026 SOLANA BEACH, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has entered into a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust (BHSCT). The study will evaluate the effects of Artelo's peripherally selective synthetic canna
SOLANA BEACH, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced that on February 27, 2026, Artelo's Board of Directors approved a 3-for-1 reverse stock split ("Reverse Split") of the Company's common stock ("Common Stock"). The Company's common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, March 10, 2026. The Board of Directors determined the 3-for-1 ratio to be
SOLANA BEACH, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended December 31, 2025. Business Highlights: Successful Phase 1 study with ART26.12: Reported positive first-in-human Phase 1 single ascending dose (SAD) clinical data demonstrating a favorable safety profile, predictable pharmacokinetics, and dosing flexibility. As a result,
SOLANA BEACH, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today commented on the White House's recent Executive Order establishing a Medicare pilot program to support reimbursement and structured data collection for cannabidiol (CBD) products. Artelo views the Administration's action as a significant milestone in the recognition of CBD's therapeutic potential and an important step toward improving access to cannabinoid-based treatments f
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
D. Boral Capital upgraded Artelo Biosciences from Hold to Buy and set a new price target of $20.00
HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00
LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy
Ladenburg Thalmann initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $7.00
D - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
SCHEDULE 13G - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
D - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
D - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
D - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
RW - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
3 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)
This live feed shows all institutional transactions in real time.
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)
Live Leadership Updates
SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointment strengthens Artelo's financial leadership as it advances its clinical pipeline and corporate growth initiatives. Mark Spring brings 30 years of experience in life sciences to his role, including f
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm
LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a
LA JOLLA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as Senior Vice President and Chief Scientific Officer. Dr. Yates is an experienced senior pharmaceutical executive, having served most recently at AstraZeneca, in significant roles across a number of functional areas including development and commercial strategy, medical affairs, and business development. Notably, Dr. Yates has been extensively involved in the life-cycle managem
LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors, effective November 30, 2020. “Dr. Reyes’ expert role and track record in taking small molecules and biologics through the development process make him an ideal addition for the next phase of Artelo’s advancement,” commented Connie Matsui, chairperson of Artelo’s Board of Directors. “We a